Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6207567 | 0.97 | OPRL1 (0.34) | OPRL1KMT2A | |
| SCHEMBL1337832 | 0.97 | — | — | |
| SCHEMBL19315560 | 0.86 | CDK5 (0.33) | OPRL1 | |
| SCHEMBL18724673 | 0.84 | OPRL1 (0.31) | OPRL1KMT2A | |
| Hydrochloric Acid SCHEMBL7214922 | 0.82 | — | — | |
| SCHEMBL23863586 | 0.82 | OPRL1 (0.31) | OPRL1 | |
| SCHEMBL21869937 | 0.82 | OPRL1 (0.31) | OPRL1 | |
| SCHEMBL20056361 | 0.82 | OPRL1 (0.31) | OPRL1 | |
| Formic Acid Methyl Ester SCHEMBL28291703 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL282454 | 0.79 | ALDH1A1 (0.48) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294785-A1 | INFLUENZA A VIRUS INHIBITION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-12-01 | — | — | US | claimed |
| WO-2010033340-A1 | INFLUENZA A VIRUS INHIBITION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-03-25 | — | — | WO | claimed |
| WO-2023081730-A1 | 4-HYDROXY-2-OXO-1,2-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | TEON THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| CN-111148734-B | Pyrrole-2-formamide compound and preparation method and application thereof | 中国医学科学院药物研究所 | 2023-01-06 | — | — | CN | disclosed |
| US-20210032202-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTE FOR TROPICAL DISEASES PTE LTD. (SG) | 2021-02-04 | — | — | US | disclosed |
| CN-111148734-A | Pyrrole-2-formamide compound and preparation method and application thereof | 中国医学科学院药物研究所 | 2020-05-12 | — | — | CN | disclosed |
| EP-2892880-B1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| EP-3144303-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | Array Biopharma, Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9556139-B2 | 6-substituted phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160355477-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2016-12-08 | — | — | US | disclosed |
| US-9464075-B2 | Influenza A virus inhibition | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-10-11 | — | — | US | disclosed |
| EP-1943226-A2 | PHENOL ETHERS AS MODULATORS OF THE OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2008075026-A1 | 4-HYDR0XY-2-0X0-2, 3 -DIHYDRO- 1, 3-BENZOTHIAZOL- 7YL COMPOUNDS FOR MODULATION OF B2-ADRENORECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008021849-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021851-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007047397-A2 | PHENOL ETHERS AS MODULATORS OF THE OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-1587796-A1 | SATURATED QUINOXALINE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2005-10-26 | — | — | EP | disclosed |
| US-20050004130-A1 | New metabotropic glutamate receptor compounds | ASTRAZENECA AND NPS PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004069813-A1 | SATURATED QUINOXALINE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | disclosed |
| CN-1282243-A | Pharmaceutical composition containing anilide derivative for antagonizing CCR5 | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004130-A1 | New metabotropic glutamate receptor compounds | GRM1, GRIN1, GRM2 | OPRL1 28/4885KMT2A 2078/4885 |
| US-20210032202-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | TPH1, TPH2, IARS2 | OPRL1 176/4885KMT2A 1467/4885 |
| US-20160355477-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | TPH1, TPH2, IARS2 | OPRL1 159/4885KMT2A 1548/4885 |
| US-20110294785-A1 | INFLUENZA A VIRUS INHIBITION | HAVCR2, MAVS, CD4 | OPRL1 3715/4885KMT2A 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.